Vitrafy Life Sciences Limited (ASX:VFY)
Australia · Delayed Price · Currency is AUD 3.810
+0.010 (0.26%)
Aug 26, 2026, 3:58 PM AEST
Vitrafy Life Sciences Income Statement
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Operating Revenue | 0.17 | 0.07 | 2.06 | 0.03 | - |
Other Revenue | 0.04 | 0.98 | 0.03 | 2.02 | 1.83 |
| 0.21 | 1.05 | 2.09 | 2.06 | 1.83 | |
Revenue Growth | -80.05% | -49.95% | 1.80% | 12.63% | - |
Cost of Revenue | 8.67 | 6.74 | - | 0.03 | 0.01 |
Gross Profit | -8.46 | -5.69 | 2.09 | 2.03 | 1.82 |
Selling, General & Admin | 11.77 | 9.85 | 2.79 | 4.35 | 3.78 |
Research & Development | - | - | 4.25 | 1.69 | 1.28 |
Other Operating Expenses | -3.45 | -0.98 | 3.69 | 3.12 | 1.37 |
Operating Expenses | 8.32 | 8.87 | 10.73 | 9.17 | 6.43 |
Operating Income | -16.78 | -14.56 | -8.64 | -7.14 | -4.61 |
Interest Expense | -0.02 | -6.49 | -10.43 | -4.99 | -2.73 |
Interest & Investment Income | 0.8 | 0.77 | - | - | - |
Currency Exchange Gain (Loss) | - | - | 0.02 | -0 | - |
Other Non Operating Income (Expenses) | -0 | -12.43 | 8.62 | 4.32 | -0.32 |
EBT Excluding Unusual Items | -16 | -32.71 | -10.43 | -7.81 | -7.66 |
Asset Writedown | -0.17 | - | - | - | - |
Pretax Income | -16.17 | -32.71 | -10.43 | -7.81 | -7.66 |
Net Income | -16.17 | -32.71 | -10.43 | -7.81 | -7.66 |
Net Income to Common | -16.17 | -32.71 | -10.43 | -7.81 | -7.66 |
Net Income Growth | - | - | - | - | - |
Shares Outstanding (Basic) | 64 | 45 | 3 | 3 | 3 |
Shares Outstanding (Diluted) | 64 | 45 | 3 | 3 | 3 |
Shares Change | 43.40% | 1359.98% | 4.02% | 0.73% | - |
EPS (Basic) | -0.25 | -0.73 | -3.40 | -2.65 | -2.62 |
EPS (Diluted) | -0.25 | -0.73 | -3.40 | -2.65 | -2.62 |
EPS Growth | - | - | - | - | - |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Free Cash Flow | -16.31 | -8.8 | -6.8 | -5.05 | -6.36 |
Free Cash Flow Per Share | -0.25 | -0.20 | -2.22 | -1.71 | -2.17 |
Gross Margin | - | - | 100.00% | 98.62% | 99.69% |
Operating Margin | -8027.61% | -1389.32% | -412.48% | -347.14% | -252.69% |
Profit Margin | -7737.44% | -3121.97% | -497.98% | -379.91% | -419.56% |
Free Cash Flow Margin | -7804.38% | -840.18% | -325.03% | -245.44% | -348.32% |
EBITDA | -16.73 | -14.48 | -8.53 | -6.98 | -4.48 |
EBITDA Margin | - | - | - | - | -245.56% |
D&A For EBITDA | 0.05 | 0.08 | 0.11 | 0.16 | 0.13 |
EBIT | -16.78 | -14.56 | -8.64 | -7.14 | -4.61 |
EBIT Margin | - | - | - | - | -252.69% |